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ABSTRACT: Chemotherapy has been shown to be effective
in reducing the progression and development of cancer in
metastatic patients. However, drug selectivity is still a major
issue for most chemotherapeutics. In this study, we
synthesized four novel heterocyclic compounds having
similarity in structure with quinone systems whereby nitrogen
atoms replace the oxygen atoms. The anticancer activity of
these compounds (DIQ3-6) was tested against HCT116
human colon cancer cells. We showed that all four
heterocycles caused significant reduction in colon cancer cell
viability at doses as low as 4 μM, a concentration that was not cytotoxic to normal human FHs74Int intestinal cell lines.
Interestingly, these heterocycles inhibited colon sphere formation in 3D cultures at first generation (G1), mainly because of
inhibition of proliferation as evidenced by Ki67 staining. Thus, DIQ3 causes sufficient eradication of the self-renewal ability of
the highly resistant cancer stem cells. This study represents the first documentation of the activity of these novel heterocyclic
compounds, particularly compound DIQ3, and their potential therapeutic use in targeting colon cancer self-renewal capacity.
Our findings provide the basis for proposing these nontoxic and stable compounds for additional testing against cancer.
■ INTRODUCTION
Over the past decades, ongoing research in the fields of
chemotherapy, radiation therapy, surgery, and others have
progressed noticeably.1,2 Despite improvements in all other
fields, chemotherapy still plays an essential role in cancer
treatment, knowing that 90% of cancer deaths are a result of
metastasis.3
Most of the drugs used in cancer chemotherapy are of
natural origin, whether from plants, microorganisms, or even
marine species.3 The active organic compounds that were
extracted from these natural sources have often been replaced
with synthetic ones.4 Recent studies have shown that some
quinones, which are often plant-derived secondary metabo-
lites,5 are active agents against cancer.6
Quinones possess a cyclic structure with two keto functional
groups.7 In an aprotic medium, each keto group can be
reduced in a one electron reduction step. The two successive
steps produce semiquinone and quinonedianion (Q2−),
respectively.8 Some of the most well-known anticancer agents
that belong to the quinone family are shown in Figure 1. It is
important to mention the belief that the chemotherapeutic
drugs adriamycin and mitomycin C act as anticancer active
agents through the redox quinone-hydroquinone system.9,10 In
addition, p-quinonimines such as the 1,2,4-benzotriazinones
have shown anticancer activity.11,12
Although more than 200 drugs have been discovered with
activity against different types of cancer, each however has its
own side effects.13 The main drawbacks of chemotherapy
include the presence of low and insufficient concentration of
the drug at the tumor site, high toxicity, and drug resistance.1
In addition, the major problem with chemotherapy is its lack of
selectivity, which leads to the death of both cancer and normal
cells.14
Targeted therapy emerged with the aim of destroying only
cancerous cells, and currently, many drugs of this sort are FDA
approved and are being used. Even though it might have
overcome the selectivity issue in some cases, targeted therapy
still causes some side effects.15
For several decades, chemotherapy drugs for metastatic
cancers have shown partial benefit as only 50% of patients
receiving therapy develop recurrence.16 Therapy failure is
believed to occur because available chemotherapeutics shrink
the tumor bulk by eliminating the chemo-sensitive clones but
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do not eradicate chemo-resistant clones or cancer stem cells
(CSCs), which replenish the tumor. Thus, the identification of
a drug that simultaneously targets CSCs and chemo-resistant
cells is of high importance for clinical treatment and for
effective eradication of some types of cancer. CSCs express
distinctive arrays of surface biomarkers, which make them
vulnerable to therapies targeting multiple possible cellular
pathways.16 In this study, we report the synthesis of four novel
heterocyclic compounds (Scheme 1); four of which were
investigated for anticancer activity against human colon cancer
HCT116 cells.
■ RESULTS AND DISCUSSION
Compound DIQ3 and its analogues (DIQ4-6) were
synthesized in four steps as illustrated in Scheme 1. All the
intermediates (3a−d, 4a−d, 5a−d) involved in these reactions
were isolated and characterized as well.
All compounds 3−5 were prepared at room temperature
because compounds 3 and 5 are unstable at high temperatures,
yielding the corresponding benzimidazole derivative in the
presence of oxygen. Also, in preparation of compounds 3 and
5, the usage of a minimum amount of solvent was very crucial
to obtain high yields.
The preparation of imine 3 was accomplished through the
mono condensation between o-phenylenediamine 1 (1 equiv)
and aldehyde 2 (1.2 equiv) at room temperature. The
formation of the imine (HCN) bond can be easily observed
in the 1H NMR because of its diagnostic CH between 8 and 9
ppm. Compound 3 was then reduced with excess NaBH4 in
methanol to afford 4. The indicative peaks for this reduction in
the 1H NMR are the disappearance of the singlet at 8−9 ppm
for the CHN and the appearance of a doublet at 4−5 ppm
for the CH2 and a broad peak at around 5 ppm corresponding
to the NH. Compound 4 (1 equiv) was further treated with 2-
cyanobenzaldehyde (1.2 equiv) in dimethyl sulfoxide (DMSO)
in addition to a few drops of acetic acid at room temperature
to afford compound 5. Upon treating orange compound 5 with
an excess of KCN (previously dissolved in water) in
acetonitrile between 60 and 65 °C, compound DIQ
precipitated out of solution as a yellow solid. In bulk, the
yellow precipitates (DIQ3-6) have a minor yellow component
which travels fast on thin-layer chromatography (TLC), which
we believe results from hydrolysis of the imino group to the
Figure 1. Structures of some anticancer quinones.
Scheme 1. Synthesis of the Different Analogues of DIQ3
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hard to isolate keto form. The pure DIQ3-6 was obtained by
leaching the yellow products with methanol to get rid of this
minor yellow impurity. All derivatives of DIQ were brightly
fluorescent, except for DIQ5, which allowed them to be easily
visualized on TLC using long wavelength UV (365 nm).
Furthermore, these compounds moved very slowly on TLC,
even with ethyl acetate−methanol (9:1) as the mobile phase.
The addition of KCN followed by a cascade of reactions to
afford the different analogs of DIQ might be explained by the
proposed mechanism shown in Scheme 2.
The following mechanism was proposed based on similar
cyanation reactions done by Haddadin et al.17
DIQ3 and Related Derivatives Reduce the Viability of
Human Colon Cancer HCT116 Cell Line in 2D in Vitro
Models at Doses That Are Not Cytotoxic to Normal
FHs74Int Cells. To assess the antitumor effect of compound
DIQ3 and its related derivatives (DIQ4-6) on human colon
cancer HCT116 cell lines, we employed the MTT assay. The
MTT results revealed that all drugs were capable of
significantly inhibiting the metabolic activity of the colon
Scheme 2. Proposed Mechanism of the Cascade Cyclization
Figure 2. DIQ3 and related derivatives reduce the viability of HCT116 cell line as assessed by MTT. The antitumor effect of different
concentrations of DIQ3 and its related derivatives (compounds DIQ4-6) on the viability of HCT116 cells was determined in sextuplicates at 24,
48, and 72 h using MTT assay. Results are expressed as percent of control. The data are reported as mean of n = 2 ± SEM (*P < 0.05, **P < 0.01
using Student’s t-test).
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cancer cells. DIQ3 and its related derivatives inhibited the
viability of HCT116 even at pharmacologically achievable
micromole concentrations in a time- and dose-dependent
manner (Figure 2). Interestingly, a DIQ3 concentration as low
as 4 μM was able to inhibit cell viability by approximately more
than 50% at 24 h. It is worth noting that the toxicity of varying
concentrations (1−10 μM) of DIQ3 and related derivatives
was investigated in FHs74Int cells derived from normal human
fetal intestinal tissue by MTT assay. Interestingly, DIQ3 and
related derivatives had relatively limited toxicity when applied
at doses up to 5 μM and over a 72 h period (Figure 3).
DIQ3 Targets an Enriched Population of Colon
Cancer Stem/Progenitor Cells. The ability to grow as
nonadherent spheroids has been widely used to assess the self-
renewal capability of CSCs. We investigated colonosphere
formation of HCT116 cells, a salient feature of CSCs. To
better visualize their sphere-forming capabilities in 3D cultures,
HCT116 cells were cultured as single cells in Matrigel for 11
days in the presence and absence of compound DIQ3 or its
derivatives. The spheres were then visualized under an inverted
Figure 3. DIQ3 and related derivatives (DIQ4-6) had relatively limited toxicity on the viability of FHs74Int cell line as assessed by MTT for doses
up to 5 μM. Experiment was performed in sextuplicates for each condition. Results are expressed as percent of control. The data are reported as
mean of n = 2 ± SEM (*P < 0.05, **P < 0.01 using Student’s t-test).
Figure 4. DIQ3 and related derivatives inhibit size and number of
HCT116 colonospheres in generation 1. Effect of DIQ3 and its
derivatives on colonospheres using sphere formation assay.
Representative bright-field images of HCT116 colon spheres in
Matrigel at generation 1/day 11. HCT116 cells were plated in
Matrigel at a density of 2000 cells/well. Images were visualized by
Axiovert inverted microscope at 20X magnification and analyzed by
Carl Zeiss Zen 2012 image software.
Figure 5. Effect of DIQ3 and its related derivatives (DIQ4-6) on
inhibiting the self-renewal ability of the HCT116 colon cancer cells in
generation 1. Cells were cultured in Matrigel at a density of 2000
cells/well for 11 days. The generated spheres are referred to as G1
(generation 1) spheres. These spheres were treated in duplicates with
increasing concentrations of the drugs (0.01, 0.1, 1 μM) or media
(Ctr). Media or treatment was replenished every 2 days. Spheres were
counted by phase contrast microscopy at day 11 of sphere culture.
Results are expressed as SFU which is calculated according to the
following formula: SFU = (number of spheres counted × (100)/
number of input cells). The data were reported as mean of n = 2 ±
SEM (*P < 0.05 using the Student’s t-test).
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light microscope and bright-field images were taken (Figure 4).
Our data showed that HCT116 had a unique population of
sphere-forming cells, suggesting the presence of cells with stem
cell-like properties. Notably, the sphere-forming unit (SFU)
was always lower in drug-treated cells compared with that of
the control condition in a dose-dependent manner. Interest-
ingly, the percent of spheres decreased to about 50% at 0.1 μM
of DIQ3 and complete inhibition of sphere formation was
achieved in wells treated with 1 μM of the compounds (Figure
5).
We assessed the presence of stem cell markers in 3-D
Matrigel culture within the HCT116 cell populations.
Immunofluorescence staining showed high expression of
CD44, CD133, and EpCAM in control HCT116 spheres at
G1 (Figure 6) indicating enriched stemness in these cells. To
understand the mechanism of inhibition of colon sphere
formation by DIQ3, we evaluated sphere proliferation by Ki67
expression and DNA apoptotic fragmentation using a Tunel
assay (Figure 7). It appeared that the mechanism of inhibition
of colon sphere formation was mainly due to inhibition of
proliferation because colon spheres that were formed in the
presence of DIQ3 had much lower Ki67 staining and were
much smaller in size compared with the control. Treatment
with 0.5 μM DIQ3 also showed Tunel-positive cells in HCT16
colon spheres as compared to the control (Figure 7).
■ CONCLUSIONS
Diminoquinone compounds (DIQ3-6) have been widely
investigated as potent anticancer agents. On the basis of the
promising anticancer activity of DIQ3, we were interested in
studying its antitumor properties in 2D and 3D models. To the
best of our knowledge, this is the first study to investigate the
synthesis of these components and the effect of DIQ3 on
colon cancer cells with stem-like properties.
Recent growing evidence suggests that the tumor has a
specialized malignant cell population, characterized by self-
renewing, multipotent, and tumor initiating properties, which
drives tumor development. This subpopulation is referred to as
cancer stem-like cells, which are generated from normal stem
or precursor cells within tissues after mutations occur.18
Discovery of these CSCs has provided a new insight into
carcinogenesis where this highly resistant population can be
held accountable for uncontrolled growth, relapse, and
metastasis. We evaluated the ability of DIQ3 to target the
subpopulation of stem/progenitor cells in HCT116 cells using
a 3D sphere formation assay. Remarkably, treatment with
DIQ3 at a concentration as low as 0.1 μM inhibited
significantly the SFU. This suggests that the therapeutic effect
of DIQ3 is exerted via targeting the CSCs. Our current
findings make DIQ3 and its derivatives somewhat selective,
which is the most essential aspect sought after in chemo-
therapeutic drugs. Thus, this study will provide the basis for
proposing DIQ3 as a nontoxic and stable compound for
additional testing.
■ MATERIALS AND METHODS
General Procedures and Reagents. Melting points were
determined using the DigiMelt apparatus and were un-
corrected. NMR spectra were determined in deuterated
DMSO on a Bruker AM 500 NMR spectrometer. Chemical
shifts are reported in ppm (δ). Infrared spectra were recorded
using Thermo Scientific iD3 ATR for Nicolet iS5 FT-IR
spectrometer. The IR bands are reported as wave numbers
(cm−1). TLC was performed on TLC Silica gel 60 F254 (used
directly as received). For high-resolution mass spectra
(HRMS), the samples were analyzed by flow-injection analysis
on a Thermo Fisher Scientific LTQ Orbitrap (San Jose, CA)
operated in the centroid mode. The samples were injected into
a mixture of 50% MeOH/H2O and 0.1% formic acid at a flow
of 0.2 mL/min. Source parameters were 5.5 kV spray voltage,
capillary temperature of 275 °C, and sheath gas setting of 20.
Spectral data were acquired at a resolution of 100 000 full
Figure 6. Human HCT116 cells possess a CSC-like population with sphere forming capacity. Representative immunofluorescence imaging of
control HCT116 G1 spheres stained for stem cell markers using CD44, CD133, and EpCAM. The nuclei were stained with antifade reagent
Fluorogel II with DAPI. Scale bar 20 μm.
Figure 7. Tunel and Ki67 staining in HCT116 colon G1 spheres.
Representative immunofluorescence imaging of control (Ctr) and
treated spheres with 0.5 μM DIQ3 after Tunel and Ki67 staining.
Scale bar 20 μm.
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width at half-maximum with the lock mass feature, which
typically results in sufficient mass accuracy.
The starting materials used were commercially available and
purchased from standard chemical suppliers.
Synthesis of DIQ3 through Intermediates 3a, 4a and
5a. (E)-2-(((2-Aminophenyl)imino)methyl)benzonitrile (3a).
o-Phenylenediamine (3.05 g, 28.2 mmol) and o-cyanobenzal-
dehyde (4.55 g, 34.7 mmol) were dissolved in ethanol (11
mL). The reaction was stirred at room temperature for 45 min.
Precipitates formed, and the solution was placed in an ice bath.
The crystals were then collected by suction filtration and
washed with cold ethanol. The desired product was obtained as
orange crystals (5.73 g, 92%), mp 99−103 °C.
1H NMR (500 MHz, DMSO-d6): δ 5.48 (s, 3H), 6.59 (ddd,
J = 8.3, 7.2, 1.4 Hz, 1H), 6.75 (dd, J = 8.1, 1.4 Hz, 1H), 7.04
(ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 7.31 (dd, J = 8.0, 1.4 Hz, 1H),
7.66 (td, J = 7.6, 1.3 Hz, 1H), 7.84 (td, J = 7.7, 1.3 Hz, 1H),
7.98 (dd, J = 7.8, 1.3 Hz, 1H), 8.08−8.22 (m, 1H), 8.87 (s,
1H);13C NMR DEPT 135 (126 MHz, DMSO-d6): δ 115.58,
116.49, 117.19, 129.61, 131.28, 131.41, 133.92, 135.25,
151.83; 13C NMR (126 MHz, CDCl3): δ 111.38, 115.91,
116.73, 118.13, 118.49, 129.40, 129.49, 130.51, 132.87, 134.24,
134.67, 138.62, 144.01, 151.28; FTIR (cm−1): 3444 (w), 3349
(w), 2216 (w), 1607 (m), 1488 (m), 1371 (w), 1311 (m),
1262 (m), 1156 (m), 753 (s); HRMS (ESI-Orbitrap) m/z: [M
+ H]+ calcd for C14H12N3
+, 222.1026; found, 222.1026.
2-(((2-Aminophenyl)amino)methyl)benzonitrile (4a). 3a
(0.81 g, 3.7 mmol) was dissolved partially in methanol (30
mL), and NaBH4 was added gradually. The solution was
orange at first and became lighter over time. At the end of the
reaction, the solution was pale yellow. The reaction was done
at room temperature, was monitored by TLC, and was
complete within 1 h. Water was added to the solution and the
product crashed out as a white precipitate. The precipitate was
then collected by suction filtration and was washed thoroughly
with water. The desired product was obtained as a white solid
(0.73 g, 90%), mp 120−123 °C.
1H NMR (500 MHz, DMSO-d6): δ 4.47 (d, J = 5.8 Hz, 2H),
4.59 (s, 2H), 5.26 (t, J = 5.8 Hz, 1H), 6.25−6.33 (m, 1H),
6.39−6.47 (m, 2H), 6.54−6.70 (m, 1H), 7.44 (td, J = 7.5, 1.3
Hz, 1H), 7.56 (dd, J = 8.0, 1.2 Hz, 1H), 7.65 (td, J = 7.6, 1.3
Hz, 1H), 7.83 (dd, J = 7.7, 1.4 Hz, 1H); 13C NMR DEPT 135
(126 MHz, DMSO-d6): δ 45.88, 110.74, 114.86, 117.94,
118.11, 128.13, 128.69, 133.36, 133.71; 13C NMR (126 MHz,
DMSO-d6): δ 45.91, 110.75, 111.07, 114.87, 117.94, 118.00,
118.12, 128.13, 128.70, 133.36, 133.70, 135.43, 136.04,
144.52; FTIR (cm−1): 3355 (w), 2224 (w), 1622 (w), 1597
(w), 1506 (m), 1458 (w), 1273 (m), 1257 (m), 1229 (w),
1142 (w), 763 (m), 740 (s); HRMS (ESI-Orbitrap) m/z: [M
+ H]+ calcd for C14H14N3
+, 224.1182; found, 224.1182.
(E)-2-(((2-((2-Cyanobenzyl)amino)phenyl)imino)methyl)-
benzonitrile (5a). 4a (0.32 g, 1.43 mmol) and 2-
cyanobenzaldehyde (0.23 g, 1.75 mmol) were dissolved in
DMSO (5 mL) and glacial acetic acid (4 drops) was added.
The reaction was kept at room temperature and orange needle-
like crystals precipitated from the solution, which were
collected by suction filtration and washed with methanol to
afford the product (0.44 g, 91%), mp 156−160 °C.
1H NMR (500 MHz, DMSO-d6): δ 4.62 (d, J = 6.4 Hz, 2H),
6.46 (t, J = 6.4 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 6.66 (t, J =
7.5 Hz, 1H), 7.04−7.14 (m, 1H), 7.36 (dd, J = 8.0, 1.4 Hz,
1H), 7.43 (t, J = 7.6 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.64
(td, J = 7.7, 1.3 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.82 (d, J =
7.7 Hz, 1H), 7.85 (t, J = 7.4 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H),
8.24 (d, J = 7.8 Hz, 1H), 8.91 (s, 1H); 13C NMR DEPT 135
(126 MHz, DMSO-d6): δ 45.27, 111.11, 117.02, 117.16,
128.27, 128.43, 129.83, 131.07, 131.64, 133.50, 133.84, 133.94,
135.00, 152.93; 13C NMR (126 MHz, DMSO-d6): δ 45.27,
110.20, 110.91, 111.12, 117.02, 117.16, 117.96, 119.32, 128.27,
128.43, 129.83, 131.07, 131.64, 133.50, 133.84, 133.94, 134.63,
135.00, 138.51, 144.09, 144.33, 152.93; FTIR (cm−1): 3388
(m), 2210 (w), 1595 (m), 1508 (m), 1488 (w), 1453 (w),
1423 (w), 1361 (w), 1327 (m), 1293 (m), 1271 (m), 1160
(m), 1043 (w), 763 (s), 738 (s); HRMS (ESI-Orbitrap) m/z:
[M + H]+ calcd for C22H17N4
+, 337.1448; found, 337.1448.
2-((5-Iminoisoquinolino[3,4-b]quinoxalin-7(5H)-yl)-
methyl)benzonitrile (DIQ3). 5a (0.065 g, 0.20 mmol) was
dissolved partially in acetonitrile (5 mL) and excess of KCN,
was dissolved previously in minimal water, and was added to
the solution and left for 24 h. The product was collected by
suction filtration and washed with cold methanol to yield
orange crystals (0.060 g, 86%). The product decomposed at
212−215 °C.
1H NMR (500 MHz, DMSO-d6): δ 5.99 (s, 2H), 7.17 (d, J
= 7.9 Hz, 1H), 7.44−7.51 (m, 3H), 7.55 (td, J = 7.7, 1.4 Hz,
1H), 7.62 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.77 (td, J = 7.4, 1.6
Hz, 1H), 7.81 (td, 1H), 7.95 (dd, J = 7.6, 1.4 Hz, 1H), 7.99
(dd, J = 7.9, 1.5 Hz, 1H), 8.40 (dd, J = 7.6, 1.6 Hz, 1H), 8.61
(dd, J = 7.6, 1.6 Hz, 1H), 8.65 (s, 1H); 13C NMR DEPT 135
(126 MHz, DMSO-d6): δ 45.50, 115.69, 124.20, 124.86,
126.90, 127.34, 128.61, 130.45, 131.52, 132.06, 132.35, 133.94,
134.16; 13C NMR (126 MHz, DMSO-d6): δ 45.50, 110.99,
115.69, 117.79, 124.21, 124.87, 126.91, 127.34, 128.62, 130.45,
131.38, 131.53, 131.96, 132.07, 132.36, 132.42, 133.94, 134.16,
134.55, 139.54, 143.91, 144.66, 160.41; FTIR (cm−1): 3260
(w), 2231 (w), 1570 (w), 1538 (m), 1526 (s), 1477 (w), 1466
(w), 1445 (w), 1389 (m), 1359 (m), 1342 (w), 1306 (m),
1184 (w), 1057 (w), 893 (m), 781 (m), 754 (m), 741 (s);
HRMS (ESI-Orbitrap) m/z: [M + H]+ calcd for C23H16N5
+,
362.1400; found, 362.1403.
The different analogs of DIQ were synthesized in a similar
manner (see Supporting Information).
Cell Culture and Treatment. HCT116 cell lines (ATCC,
USA) were cultured and maintained in RPMI 1640 (Sigma-
Aldrich, UK) with 20 mM HEPES and L-glutamine. Cells were
maintained in an incubator at 37 °C in a humidified
atmosphere of 5% CO2 and 95% air. Cell culture media was
supplemented with antibiotics [1% penicillin−streptomycin
(100 U/mL)], 10% heat-inactivated fetal bovine serum (FBS)
(Sigma-Aldrich, Germany), and 5 μg/mL Plasmocin prophy-
lactic (InvivoGen). FHs74Int, normal human fetal intestinal
cell line, was grown in Dulbecco’s modified Eagle’s medium
with 10% FBS at 37 °C under 5% CO2. Cells were incubated at
37 °C in a humidified incubator containing 5% CO2. Stocks of
the compounds DIQ3-6 were prepared by dissolving 5 mg in 1
mL of DMSO. Dilutions were prepared such that the
percentage of DMSO on cells was less than 0.1%.
MTT Assay. The effects of compounds DIQ3-6 on cell
viability was measured in vitro using the MTT ([3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]) assay.
Colon cancer and normal FHs74Int cells were plated in 96-
well culture plates at 5 × 103 cells/well and incubated
overnight and then treated in sextuplicates with 0.1% DMSO
or different concentrations of compounds DIQ3-6 for 24, 48,
or 72 h. For each time point, 10 μL of 5 mg/mL (in 1× PBS)
MTT reagent was added to each well and incubated at 37 °C
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for 4 h, after which 100 μL of solubilizing solution was added.
After overnight incubation, the reduced MTT optical density
was measured at a wavelength of 595 nm using an ELISA
reader (Multiskan Ex). The percentage of viable cells was
determined for each drug concentration with respect to
untreated cells and is represented as mean ± standard error
of the mean (SEM).
3D Culture and Sphere-Formation Assay. This assay
was performed according to the protocol previously
described.19−21 2000 cells/well were suspended in cold
Matrigel/serum-free medium (1:1) in a total volume of 50
μL. HCT116 cells were seeded uniformly in a circular manner
around the bottom rim of the well and allowed to solidify in
the incubator at 37 °C for 1 h. Subsequently, 0.5 mL of low-
serum media treated with compounds DIQ3-6 or DMSO was
added gently in the middle of each well. Spheres were
replenished with warm media as in the original seeding every
other day. Spheres were counted after 10−13 days. To
propagate spheres, the medium was aspirated and Matrigel was
digested with 0.5 mL of 1 mg/mL dispase solution (Invitrogen,
Carlsbad, CA), dissolved in serum-free medium for 60 min at
37 °C. Spheres were then collected and incubated in 1 mL
warm trypsin/EDTA at 37 °C for 5 min and then passed
through a 20, 25, and 27-gauge syringes three times. Cells were
counted using a hemocytometer and re-seeded as described
above. The sphere-formation unit (SFU) was calculated for
each generation as follows: SFU = (number of spheres
formed/number of cells plated) × 100. Results were
represented as a percentage of the SFU of the treated spheres
compared with the untreated ones. Zeiss Axiovert microscope
was used for the acquisition of bright field images.
Tunel Assay. Spheres were collected between days 10 and
13 and fixed for 15 min at 15−25 °C. Spheres were incubated
overnight in 70% ethanol at 4 °C. The next day, spheres were
washed with PBS and then incubated in 50 μL/condition
Tunel reaction mixture for 60 min at room temperature. After
embedding the stained spheres with antifade, a Carl Zeiss LSM
710 laser scanning confocal microscope was used for
immunofluorescence analysis.
Immunofluorescence Staining. Collected spheres were
immunostained with primary mouse monoclonal anti-Ki67 (1/
150 dilution) antibody (Santa Cruz Biotechnology, CA) and
secondary Alexa 488 goat anti-mouse (Invitrogen, CA)
antibody. Spheres were mounted with the anti-fade Fluoro-
gel II with Dapi. Confocal microscopic analyses were
performed using a Carl Zeiss LSM 710 laser scanning confocal
microscope and images were acquired and analyzed using the
Carl Zeiss ZEN 2012 image software.
Statistical Analysis. Data were analyzed using the
Student’s t-test. P-values of p < 0.05 (*) and p < 0.01 (**)
were considered significant and highly significant, respectively.
Results are presented as the mean ± standard error (SEM).
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